Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baxalta Incorporated

http://www.baxalta.com/

Latest From Baxalta Incorporated

A Promising Future For Oncolytic Viruses As Cancer Immunotherapies

The development of oncolytic virus therapy has gained momentum over the past decade, due to its relatively safe mode of action and potential to enhance existing treatment options. A third of cancer vaccines in development are now oncolytic viruses, which are being developed for about 40 different types of cancer. In Vivo takes a closer look at therapies in development to see what the future holds for this promising therapy.

Cancer ImmunoOncology

Anthos Takes On Pharma Giants In Factor XI Anticoagulation Space

CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.

Cardiovascular Innovation

Takeda Expands Hemophilia Play In India But Hemlibra Has Made Inroads

Takeda dips into the ex-Shire portfolio to debut Adynovate in India, where a large number of hemophilia patients remain undiagnosed. The extended half-life recombinant Factor VIII treatment, though, will need to take on competitors like Roche’s blockbuster, Hemlibra, which has seen rapid adoption in reimbursement ecosystems where it is included in the formulary

Commercial India

Anthos CEO On When Big Promo Efforts Are Needed, Telehealth's Acute Care Promise

Anthos Therapeutics’ CEO and ex-head of global commercial operations at Novartis Pharma, John Glasspool, says there’s no "automatic premise" that the large promotional launch model is broken. He also outlines how teleconsultation is taking medicine back to its roots and "where it can be" as well, with patients less likely to get white coat syndrome. 

Commercial Digital Health
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • AesRX LLC
    • Chatham Therapeutics
    • Gambro AB
    • Immuno-US
    • Prism Pharmaceuticals, Inc.
    • SuppreMol GmbH
    • Synovis Life Technologies, Inc.
UsernamePublicRestriction

Register